Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 6/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.39 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598255 | 1.00 | KLK7 (0.45) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL1908567 | 1.00 | KLK7 (0.45) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL3424651 | 1.00 | KLK7 (0.45) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL17169858 | 0.94 | KLK7 (0.50) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL29997836 | 0.94 | KLK7 (0.50) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL19605628 | 0.88 | KLK7 (0.45) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL18724921 | 0.88 | KLK7 (0.45) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL19605627 | 0.88 | KLK7 (0.45) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL9963887 | 0.88 | KLK7 (0.45) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL12519985 | 0.87 | KLK7 (0.47) | KLK7KLK5PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802887-B2 | Process for the preparation of intermediates useful for the manufacture NEP inhibitors | NOVARTIS AG (CH) | 2017-10-31 | — | — | US | disclosed |
| US-9403766-B2 | Intermediates for producing NEP inhibitors or prodrugs thereof | NOVARTIS AG (CH) | 2016-08-02 | — | — | US | disclosed |
| US-20160060217-A1 | Processes | HOOK DAVID (CH) | 2016-03-03 | — | — | US | disclosed |
| US-9227934-B2 | Processes for producing NEP inhibitors or prodrugs thereof | NOVARTIS AG (CH) | 2016-01-05 | — | — | US | disclosed |
| US-9206116-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-12-08 | — | — | US | disclosed |
| US-20150274650-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | HOOK DAVID (CH) | 2015-10-01 | — | — | US | disclosed |
| US-20150246881-A1 | Processes | NOVARTIS AG (CH) | 2015-09-03 | — | — | US | disclosed |
| US-9085529-B2 | Process for the preparation of intermediates useful for the manufacture NEP inhibitors | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-9061973-B2 | Processes for producing NEP inhibitors or prodrugs thereof | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150166468-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | NOVARTIS AG (CH) | 2015-06-18 | — | — | US | disclosed |
| US-8993785-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20140249320-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-20140243546-A1 | Processes | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-8716495-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2014-05-06 | — | — | US | disclosed |
| US-8580974-B2 | Processes | NOVARTIS AG (CH) | 2013-11-12 | — | — | US | disclosed |
| US-20130158275-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | disclosed |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20110046397-A1 | NEW PROCESSES | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-02-24 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060217-A1 | Processes | MME, NAT1, AGTR1 | KLK7 2704/4885KLK5 1869/4885PRSS1 509/4885 |
| US-20110046397-A1 | NEW PROCESSES | MME, REN, AGTR1 | KLK7 2766/4885KLK5 1892/4885PRSS1 569/4885 |
| US-20130158275-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | MME, DNPEP, REN | KLK7 2897/4885KLK5 1766/4885PRSS1 202/4885 |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | MME, REN, PAH | KLK7 3403/4885KLK5 1873/4885PRSS1 363/4885 |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | MME, REN, PAH | KLK7 3403/4885KLK5 1873/4885PRSS1 363/4885 |
| US-20140249320-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | MME, REN, PAH | KLK7 3403/4885KLK5 1873/4885PRSS1 363/4885 |
| US-20150166468-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | MME, REN, PAH | KLK7 3403/4885KLK5 1873/4885PRSS1 363/4885 |
| US-20150274650-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | MME, DNPEP, REN | KLK7 2446/4885KLK5 1752/4885PRSS1 364/4885 |
| US-20140243546-A1 | Processes | MME, NAT1, AGTR1 | KLK7 2704/4885KLK5 1869/4885PRSS1 509/4885 |
| US-20150246881-A1 | Processes | MME, NAT1, AGTR1 | KLK7 2704/4885KLK5 1869/4885PRSS1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.